Articles tagged with Rotavirus
Researchers have developed a strain of engineered rice that produces a rotavirus-specific antibody, protecting both normal and immune-deficient mice from the disease. This study provides a low-cost strategy for preventing rotavirus infection.
Researchers developed a strain of rice that produces a rotavirus-specific antibody, protecting both normal and immune-deficient mice. The engineered rice maintains its efficacy even after long-term storage and heat exposure.
Researchers have developed a vaccine that provides at least 60 percent protection against rotavirus in newborns, significantly reducing severe dehydration and hospitalizations. The study, published in the Journal of Infectious Diseases, suggests that early administration of the vaccine could save thousands of lives annually.
The India-developed rotavirus vaccine ROTAVAC has demonstrated excellent safety and efficacy in a Phase III clinical trial, reducing severe rotavirus diarrhoea by over half. The vaccine's impact extends beyond rotavirus infections, also showing protection against severe diarrhoea of any cause.
Research suggests that targeting four specific pathogens, including rotavirus and ETEC, could reduce diarrheal deaths in children by up to 40%. The study found that malnutrition is a major risk factor for severe diarrhea, highlighting the need for preventive strategies.
A new study published in Clinical Infectious Diseases found that vaccinating children against rotavirus indirectly protects unvaccinated adults from severe diarrhea and vomiting. The study suggests pediatric immunization may be more cost-effective than previously thought due to reduced health care costs among adults.
Researchers at Virginia Tech Carilion Research Institute invent a way to directly image biological structures at their most fundamental level, providing a gateway to understanding dynamic systems in structural biology. The technique has successfully imaged viruses and other biological structures in their natural environments.
Lifting age restrictions on rotavirus vaccination in low- and middle-income countries could prevent up to 203,000 rotavirus deaths while potentially causing 547 intussusception deaths. The World Health Organization supports removing age restrictions where benefits outweigh risks.
CSIRO will produce a large quantity of antibodies specific to rotavirus strains used in developing vaccines, aiding the project's goal of increasing access and effectiveness of existing commercial vaccines worldwide. The production facility will supply antibodies for five years, supporting the development of new, affordable rotavirus v...
Researchers found that rotavirus incidence is higher during the coldest, driest months of the year in South Asia. They also discovered an association between rotavirus and vegetation density, suggesting a potential tool for disease surveillance and prevention.
The introduction of rotavirus vaccines in developing countries is projected to save more than 2.4 million lives by 2030, with significant reductions in hospitalizations and clinical visits. Rotavirus vaccines are highly cost-effective, reducing child deaths by up to 95% in GAVI-eligible countries.
Baylor College of Medicine researchers found that the P[14] strain of rotavirus uses the histo-blood group antigen A as a receptor to infect human cells. Laboratory tests showed that cells with this antigen were easily infected, while those without it were not.
Rotavirus causes severe diarrhea in babies worldwide, resulting in over 450,000 deaths annually. Canada should ensure all infants are vaccinated and support GAVI funding to sustain the vaccine's sustainability.
A study found no association between the rotavirus vaccine and an increased risk of intussusception in US infants. Researchers analyzed almost 800,000 doses administered from 2006-2010 and found no statistically significant increase in risk for all doses combined or dose-specific analyses.
A new US study confirms that updated rotavirus vaccines do not increase the occurrence of severe bowel obstruction, a potentially fatal side effect. The re-introduction of these vaccines has been credited with reducing diarrhea-related hospitalizations among children.
New research reveals that rotavirus vaccination has limited impact on deaths in middle-income countries, with most fatalities occurring in low-income nations like India and Africa. Introducing effective vaccines in these countries could substantially reduce global deaths attributable to diarrheal disease.
A University of Pittsburgh study found that introducing new vaccines can decrease vaccine availability by up to two-thirds due to storage and transportation issues. Computational models can forecast the impact of new vaccine introduction and identify potential disruptions.
A study by the CDC found that rotavirus vaccination in infants reduces hospitalizations for severe diarrhea in older children and adults. The study, published in The Journal of Infectious Diseases, shows that vaccinating infants can indirectly prevent serious disease in unvaccinated groups.
The rotavirus vaccine has dramatically decreased hospitalization rates for gastroenteritis among infants and older children. In the US, vaccination led to a 87-96% reduction in rotavirus hospitalizations among eligible children between 6 months and 24 months.
A Brazilian study shows that widespread rotavirus vaccination in all areas of the country led to significant reductions in diarrhea-related deaths and hospital admissions among young children. The authors conclude that this real-world data supports the use of rotavirus vaccination as an effective measure for controlling severe childhoo...
The MSD Wellcome Trust Hilleman Laboratories is conducting a feasibility study to develop a rotavirus vaccine designed specifically for developing country needs. The project aims to improve product stability, ease of use, transportation, and affordability.
Researchers developed a new approach to vaccination for rotavirus, inducing an immune response in mice and protecting them from infection. The heat-stable vaccine is low-cost and can be delivered as nasal drops or spray, addressing challenges in developing countries.
Scientists are assessing the impact of new vaccines on respiratory infections and diarrheal diseases in African children. The study aims to investigate how effective these vaccines are in areas with high morbidity rates and diverse strains of bacteria.
Trials in Asia and Africa have demonstrated the rotavirus vaccine's ability to prevent severe gastroenteritis and save thousands of lives. The vaccine has shown promise in reducing disease incidence, especially among infants.
Researchers at UGA used a patented signal-enhancing technique to detect and identify Group A rotaviruses in under one minute with over 96% accuracy. This method has the potential to improve public health by providing information on genotypes, aiding in epidemic monitoring and controlling disease.
A study found that vaccinating infants against rotavirus significantly reduced U.S. hospitalization rates for acute gastroenteritis, with a 28-50% decrease among young children. The vaccine prevented an estimated 55,000 hospitalizations during the 2008 season.
Rotavirus vaccination effectively reduces cases of severe rotavirus disease by 72-93% and all cases of diarrhoea by 76-67%. The vaccines are not associated with increased serious adverse events.
Studies in Mexico and Africa demonstrate a significant reduction in diarrheal disease deaths following rotavirus vaccine introduction. The findings highlight the importance of vaccination in reducing severe rotavirus infections among children in developing countries.
The rotavirus vaccine has been shown to prevent severe diarrhoea in African children, with a 61.2% reduction in incidence. The vaccine's efficacy was lower in Malawi compared to South Africa, but it still demonstrated significant impact in reducing mortality rates.
A University of North Carolina at Chapel Hill researcher has been awarded a four-year grant to study the effectiveness of rotavirus vaccines in Nicaragua. The study aims to determine how well the vaccine works in developing countries and identify shifts in rotavirus strains as a result of immunization programs.
The study shows that the timing of rotavirus epidemics depends on birth rates in the population, with higher birth rates leading to earlier outbreaks. New vaccines may reduce the frequency and severity of these outbreaks, potentially shifting the age at which infection appears in children.
Researchers found a negative correlation between birth rates and the timing of rotavirus epidemics. With declining birth rates, outbreaks occur later in the year, particularly in California.
Researchers have mapped the structure of an antiviral antibody clamped onto rotavirus protein VP7, revealing intimate details about how it interferes with virus infection. The discovery may lead to the development of a new generation of rotavirus vaccines that are easier to store and administer.
Scientists identify a common vulnerability in rotaviruses, enabling the development of a broad-spectrum treatment for severe diarrheal diseases. This breakthrough could lead to improved vaccines and medications to prevent or treat rotavirus infections.
Researchers will develop oral vaccines against tetanus and rotavirus, targeting vulnerable infants and young children. The goal is to create a vaccine that doesn't contain live bacteria and has fewer side effects.
Researchers from KEMRI-Wellcome Trust Research Programme assess rotavirus diarrhoea in young children, finding over 2% hospital admissions. Meanwhile, PLOS Medicine article discusses evidence-based TB diagnosis, citing the importance of strong evidence backing expenditure on diagnostics.
Researchers have identified two integrin receptors on intestinal cells that are used by rotavirus to cause diarrhea. The study provides new insights into the mechanism of rotavirus infection and may lead to the development of treatments to block this interaction.
A phase III study of 15,183 healthy infants found that two doses of an oral live attenuated human rotavirus vaccine reduced cases of severe gastroenteritis by 32% compared to placebo. The vaccine efficacy was 80.5-82.1% against the wild-type G1 rotavirus strain.
A rotavirus vaccine has been shown to be highly effective in preventing gastroenteritis episodes in children, with high protection rates against all severities of the condition. The vaccine also significantly reduces the need for hospital treatment and medical attention related to gastroenteritis.
Researchers discovered that soy isoflavone genistin significantly reduced rotavirus infectivity by 33-74%, with the active component being genistin alone. The study found an effective range of concentrations, and the results held up even in high levels of rotavirus exposure.
Johns Hopkins students develop a thin film drug-delivery system that dissolves in the mouth, coating with a material protecting it in the stomach and releasing the vaccine in the small intestine. The system could make rotavirus vaccine more accessible to children in developing nations.
A new study found that rotavirus, a common cause of diarrhea in children, can also be present systemically, with infectious virus detected in the blood of infected children. The presence of virus in the blood is directly related to the presence of antigen but independent of diarrhea.
A new oral vaccine, Rotateq, has been shown to virtually eliminate the most severe cases of rotavirus, a common childhood virus. The vaccine nearly eliminated serious rotavirus-related gastroenteritis and reduced hospital admissions by 96%.
The rotavirus vaccine candidate demonstrated 85% protection against severe disease and 100% protection against more severe disease in a double-blind, placebo-controlled trial. The vaccine also showed lower incidence of serious adverse events compared to placebo, with no increased risk of intussusception observed.
Dr. Albert Z. Kapikian receives the Sabin Gold Medal for developing the first licensed rotavirus vaccine, saving millions of lives worldwide. His pioneering work in electron microscopy and virus characterization has been widely recognized by NIAID Director Anthony Fauci and H.R. Shepherd.
Researchers at Boston Children's Hospital have made a breakthrough in understanding how rotavirus enters cells, paving the way for a new and safer vaccine. The study used crystallography and electron microscopy to determine the geometric structure of the virus's surface protein VP4, revealing its entry mechanism.
The NIAID-licensed rotavirus vaccine has been developed to combat severe diarrhea in infants and young children worldwide. The vaccine has shown promise in reducing the number of deaths caused by rotavirus infections, particularly in developing countries where access to effective treatments is limited.
Researchers describe atomic structure of rotavirus protein NSP2, which drives viral genome replication and packaging. Identifying this protein as a potential target for anti-viral drugs could help combat rotavirus infections.
Researchers found surprising parallels in RNA virus replication, suggesting a common strategy to kill various viruses. The discovery could lead to more general virus control strategies.
A recent study suggests that the rotavirus vaccine did not increase the risk of intussusception, a rare bowel blockage, in infants under 1 year old. The study found a 4-10% decline in hospitalizations for intussusception during the period when the vaccine was available.
A recent study found that Rotashield may trigger intussusception events in susceptible infants, but these risks are compensated for by a lower risk of intussusception later in infancy. The study analyzed hospital admissions of infants with intussusception in ten US states during the period when Rotashield was in use.
A hospital-based study in Malawi found that children with HIV were less likely to develop rotavirus infection and shed the virus, but were more likely to die from diarrhea. The study's results encourage further research into the safety of rotavirus vaccines for HIV-infected infants.
The AVANT rotavirus vaccine demonstrated nearly 90% efficacy in preventing rotavirus disease in infants, surpassing existing vaccines' 49-68% efficacy rates. The vaccine was also found to be safe and immunogenic, with minimal side effects reported.